SPDR S&P Biotech ETF
738 hedge funds and large institutions have $8.01B invested in SPDR S&P Biotech ETF in 2023 Q4 according to their latest regulatory filings, with 142 funds opening new positions, 170 increasing their positions, 268 reducing their positions, and 67 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
738
Holders Change
+65
Holders Change %
+9.66%
% of All Funds
10.82%
Holding in Top 10
23
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+35.29%
% of All Funds
0.34%
New
142
Increased
170
Reduced
268
Closed
67
Calls
$2.01B
Puts
$3.26B
Net Calls
-$1.25B
Net Calls Change
-$765M
Top Buyers
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$397M |
| 2 |
Morgan Stanley
New York
|
+$302M |
| 3 |
CHP
Castle Hook Partners
New York
|
+$161M |
| 4 |
MCM
Moore Capital Management
New York
|
+$155M |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$121M |
Top Sellers
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$414M |
| 2 |
Goldman Sachs
New York
|
-$238M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$198M |
| 4 |
Citigroup
New York
|
-$135M |
| 5 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$84.5M |
